Given the strong correlation between body weight, hepatic steatosis, T2D, and elevated fetuin-A levels in both human and animal models, weight loss strategies in NAFLD/MASLD patients with obesity are expected to result in decreased fetuin-A levels, contributing to normalization of hepatic steatosis. This evidence concerns the gene AHSG and metabolic dysfunction-associated steatotic liver disease.